How does lecanemab treat alzheimer's disease?

Lecanemab: A Novel Approach to Treating Alzheimer's Disease

Lecanemab, a human monoclonal antibody, is being developed and tested for the treatment of early symptomatic Alzheimer's disease (AD). Its mechanism of action involves targeting and removing amyloid-beta plaques from the brain, a hallmark of AD [1]. Developed by Eisai Co. Ltd. and Biogen Inc., lecanemab is designed to address the underlying pathology of the disease.

Targeting Amyloid-Beta Pathology

Lecanemab selectively binds to aggregated amyloid-beta 42 peptides, which accumulate in the brains of individuals with AD. By binding to these toxic plaques, lecanemab facilitates their clearance, reducing their impact on brain function and potentially slowing disease progression [2]. Studies have shown that lecanemab can decrease amyloid-beta levels, reduce brain inflammation, and improve cognitive function in patients with early-stage AD [3].

How Does Lecanemab Compare with Other Treatments?

Compared to existing treatments for AD, which focus mainly on managing symptoms, lecanemab addresses the underlying cause of the disease by targeting amyloid-beta plaques. Its unique approach differentiates it from other Alzheimer's treatments, such as aducanumab, which also targets amyloid-beta but has a more complicated history and controversy around its efficacy [4]. The development of lecanemab has sparked interest in the possibility of preventing or slowing AD progression, rather than merely managing symptoms.

Timeline and Regulatory Status

The clinical development of lecanemab began in 2014, with multiple studies conducted to assess its safety and efficacy in patients with early symptomatic AD [5]. In early 2022, the U.S. Food and Drug Administration (FDA) granted lecanemab a Breakthrough Therapy designation, acknowledging its potential to address an unmet medical need in the treatment of AD [6]. However, in March 2022, Biogen and Eisai announced a temporary halt in lecanemab's clinical development due to potential safety concerns regarding amyloid-related imaging abnormalities (ARIA-E). Eisai announced its lecanemab development strategy is moving forward under the name Leqembi after a regulatory approval in the U.S.

Sources:

[1] Lecanemab - Wikipedia: https://en.wikipedia.org/wiki/Lecanemab

[2] Eisai Co. Ltd. and Biogen Inc. - Clinical Trials: https://www.eisai.com/collaborations/clinical-trials-lecanemab.html

[3] Eisai Co. Ltd. - Press Release: https://www.eisai.com/news/pressrelease/2020/news20200127_1.html

[4] Aducanumab - Wikipedia: https://en.wikipedia.org/wiki/Aducanumab

[5] ClinicalTrials.gov: https://ClinicalTrials.gov/show/NCT02257411

[6] Breakthrough Therapy - U.S. Food and Drug Administration: https://www.fda.gov/RegulatoryInformation/LawsEnforcedbyFDA/SignificantAmendmentstotheFDCA/FDASIA/ucm286959.htm